The ROAD Concept: A Mechanism-Guided Approach to Antimicrobial Therapy for Carbapenemase-Producing Bacteria

Carbapenemase-producing Gram-negative bacteria are among the most challenging pathogens encountered in contemporary infectious diseases and critical care practice. Although antimicrobial susceptibility testing remains the cornerstone of laboratory diagnosis, reliance on the minimum inhibitory concentration (MIC) in isolation is insufficient to predict clinical outcome. The activity of a given regimen is governed by an interplay of factors that extends well beyond the static, in vitro MIC value: the specific carbapenemase produced (Ambler class A, B or D), co-existing resistance determinants such as porin loss, efflux-pump over-expression and AmpC hyperproduction, the infecting species and its intrinsic resistome, the anatomical site of infection and the antibiotic exposure actually achievable there, and the markedly altered pharmacokinetics of critically ill patients. This narrative review synthesizes recent evidence, with an emphasis on literature published between 2021 and 2026, on the molecular epidemiology of carbapenemases; the mechanism-specific activity of novel beta-lactam/beta-lactamase-inhibitor combinations (ceftazidime-avibactam, meropenem-vaborbactam, imipenem-cilastatin-relebactam, aztreonam-avibactam, cefepime-taniborbactam, and cefepime-enmetazobactam); cefiderocol; sulbactam-durlobactam; and legacy agents, alongside species-specific resistance patterns in Klebsiella pneumoniae, Pseudomonas aeruginosa and Acinetobacter baumannii. Particular attention is paid to tissue and cerebrospinal fluid penetration and to pharmacokinetic/pharmacodynamic optimization strategies-including extended and continuous infusion, correction for augmented renal clearance and hypoalbuminemia, and therapeutic drug monitoring-that are essential in the critically ill. We propose ROAD, a practical four-step educational checklist that organizes established, mechanism-guided prescribing principles (Resolve the resistance mechanism, Organism and actual susceptibility, Anatomical site and source control, Dose, delivery and dynamic review), and provide summative tables mapping carbapenemase class to guideline-based agents and antibiotic exposure across key infection sites. ROAD is intended for carbapenem-resistant Gram-negative infection in which carbapenemase production is suspected or must be excluded; non-carbapenemase mechanisms are considered as differential diagnoses within the checklist. ROAD has not been prospectively validated; its effect on prescribing and clinical outcomes requires prospective evaluation.

Authors

Institutions

Publication Details

Journal
Biomedicines
Published
2026-11-17
DOI
https://doi.org/10.3390/biomedicines14112659
Primary Topic
Antibiotic Resistance in Bacteria
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

The ROAD Concept: A Mechanism-Guided Approach to Antimicrobial Therapy for Carbapenemase-Producing Bacteria

María A. Bodí, Alejandro H. Rodríguez, Ester Picó-Plana, M. Salavert et al.
4 links
Biomedicines
Antibiotic Resistance in Bacteria
article

The ROAD Concept: A Mechanism-Guided Approach to Antimicrobial Therapy for Carbapenemase-Producing Bacteria

María A. Bodí, Alejandro H. Rodríguez, Ester Picó-Plana, M. Salavert, Frederic Gómez‐Bertomeu, E Esteve Pitarch, Francisco Javier Candel, Laura Claverías, Laura Canadell
article en

Abstract

Carbapenemase-producing Gram-negative bacteria are among the most challenging pathogens encountered in contemporary infectious diseases and critical care practice. Although antimicrobial susceptibility testing remains the cornerstone of laboratory diagnosis, reliance on the minimum inhibitory concentration (MIC) in isolation is insufficient to predict clinical outcome. The activity of a given regimen is governed by an interplay of factors that extends well beyond the static, in vitro MIC value: the specific carbapenemase produced (Ambler class A, B or D), co-existing resistance determinants such as porin loss, efflux-pump over-expression and AmpC hyperproduction, the infecting species and its intrinsic resistome, the anatomical site of infection and the antibiotic exposure actually achievable there, and the markedly altered pharmacokinetics of critically ill patients. This narrative review synthesizes recent evidence, with an emphasis on literature published between 2021 and 2026, on the molecular epidemiology of carbapenemases; the mechanism-specific activity of novel beta-lactam/beta-lactamase-inhibitor combinations (ceftazidime-avibactam, meropenem-vaborbactam, imipenem-cilastatin-relebactam, aztreonam-avibactam, cefepime-taniborbactam, and cefepime-enmetazobactam); cefiderocol; sulbactam-durlobactam; and legacy agents, alongside species-specific resistance patterns in Klebsiella pneumoniae, Pseudomonas aeruginosa and Acinetobacter baumannii. Particular attention is paid to tissue and cerebrospinal fluid penetration and to pharmacokinetic/pharmacodynamic optimization strategies-including extended and continuous infusion, correction for augmented renal clearance and hypoalbuminemia, and therapeutic drug monitoring-that are essential in the critically ill. We propose ROAD, a practical four-step educational checklist that organizes established, mechanism-guided prescribing principles (Resolve the resistance mechanism, Organism and actual susceptibility, Anatomical site and source control, Dose, delivery and dynamic review), and provide summative tables mapping carbapenemase class to guideline-based agents and antibiotic exposure across key infection sites. ROAD is intended for carbapenem-resistant Gram-negative infection in which carbapenemase production is suspected or must be excluded; non-carbapenemase mechanisms are considered as differential diagnoses within the checklist. ROAD has not been prospectively validated; its effect on prescribing and clinical outcomes requires prospective evaluation.

BiomedicinesVol. 14(11)
Hospital Clínico San Carlos (ES), Hospital Universitari i Politècnic La Fe (ES), Instituto de Investigación Sanitaria del Hospital Clínico San Carlos (ES), Centro de Investigación Biomédica en Red de Enfermedades Respiratorias (ES), Institut de Recerca Biomèdica Catalunya Sud (ES), Centre for Biomedical Network Research on Rare Diseases (ES), Hospital Sant Pau i Santa Tecla (ES), Hospital Universitari Joan XXIII de Tarragona (ES), Medical Research Network (US), Centro de Investigación Biomédica en Red Enfermedades Infecciosas (ES), Universitat Rovira i Virgili (ES)
Good health and well-being
Antibiotic Resistance in Bacteria
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon